These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Pharmacological mechanisms of the treatment of dyskinesias in Parkinson disease]. Jiménez-Jiménez FJ; Molina JA; Ortí-Pareja M Rev Neurol; 1999 May 1-15; 28(9):889-98. PubMed ID: 10390756 [TBL] [Abstract][Full Text] [Related]
7. [New perspectives in the treatment of the motor complications associated with chronic treatment of Parkinson disease]. Linazasoro G Neurologia; 1999 Oct; 14(8):393-406. PubMed ID: 10609463 [No Abstract] [Full Text] [Related]
8. L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach. Rascol O Mov Disord; 1999; 14 Suppl 1():19-32. PubMed ID: 10493400 [No Abstract] [Full Text] [Related]
9. [L-dopa effectiveness decreases over time. What helps Parkinson patients stay mobile?]. Wedekind S MMW Fortschr Med; 2005 Jun; 147(22):10. PubMed ID: 15977622 [No Abstract] [Full Text] [Related]
10. Ropinirole as compared with levodopa in Parkinson's disease. Frucht S N Engl J Med; 2000 Sep; 343(12):885. PubMed ID: 11001686 [No Abstract] [Full Text] [Related]
11. Peak-dose dyskinesia; an acceptable price for mobility in late-stage Parkinson's disease? Wenzelburger R Clin Neurophysiol; 2005 Sep; 116(9):1997-8. PubMed ID: 16055380 [No Abstract] [Full Text] [Related]
12. The NMDA antagonist budipine can alleviate levodopa-induced motor fluctuations. Spieker S; Löschmann PA; Klockgether T Mov Disord; 1999 May; 14(3):517-9. PubMed ID: 10348483 [No Abstract] [Full Text] [Related]
13. Current controversies: levodopa in the treatment of Parkinson's disease. Sharma JC; Vassallo M; Ross IN Mov Disord; 2005 May; 20(5):642-3; author reply 643-4. PubMed ID: 15732129 [No Abstract] [Full Text] [Related]
14. Quetiapine as treatment for dopaminergic-induced dyskinesias in Parkinson's disease. Baron MS; Dalton WB Mov Disord; 2003 Oct; 18(10):1208-9. PubMed ID: 14534933 [No Abstract] [Full Text] [Related]
15. Initiating droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease. Claassen D; Lew M Clin Auton Res; 2017 Jul; 27(Suppl 1):13-14. PubMed ID: 28631224 [No Abstract] [Full Text] [Related]
16. Kinetic-dynamic monitoring of levetiracetam effects in patients with Parkinson disease and levodopa-induced dyskinesias. Contin M; Martinelli P; Albani F; Scaglione C; Avoni P; Rizzo G; Baruzzi A Clin Neuropharmacol; 2007; 30(2):122-4. PubMed ID: 17414945 [No Abstract] [Full Text] [Related]
17. Levodopa in the treatment of Parkinson's disease: current controversies. Gerlach M; Reichmann H; Riederer P Mov Disord; 2005 May; 20(5):643; author reply 643-4. PubMed ID: 15732130 [No Abstract] [Full Text] [Related]
18. Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease. Fox S; Silverdale M; Kellett M; Davies R; Steiger M; Fletcher N; Crossman A; Brotchie J Mov Disord; 2004 May; 19(5):554-60. PubMed ID: 15133820 [TBL] [Abstract][Full Text] [Related]
19. Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations. Furukawa Y; Filiano JJ; Kish SJ Mov Disord; 2004 Oct; 19(10):1256-8. PubMed ID: 15389992 [TBL] [Abstract][Full Text] [Related]
20. The effect of levetiracetam on levodopa induced dyskinesia in patients with Parkinson's disease. Tousi B; Subramanian T Parkinsonism Relat Disord; 2005 Aug; 11(5):333-4. PubMed ID: 15949966 [No Abstract] [Full Text] [Related] [Next] [New Search]